tbuckley/cabot-search huggingface dataset:
In Vitro Reversal of Depressed T-Lymphocyte Function in the Peripheral Blood of Brain Tumor Patients&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: G W Wood, R A Morantz
Journal: JNCI Journal of the National Cancer Institute (1982)

Journal Article In Vitro Reversal of Depressed T-Lymphocyte Function in the Peripheral Blood of Brain Tumor Patients Get access Gary W. Wood, Gary W. Wood Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert A. Morantz Robert A. Morantz Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 68, Issue 1, January 1982, Pages 27–33, https://doi.org/10.1093/jnci/68.1.27 Published: 01 January 1982 Article history Received: 28 October 1980 Revision received: 24 July 1981 Accepted: 20 August 1981 Published: 01 January 1982
JUXTA-ARTICULAR NODES..
Authors: T. SALAMON
Journal: British Journal of Dermatology (1957)

Journal Article JUXTA‐ARTICULAR NODES.: An Account of a Case. Get access T. SALAMON T. SALAMON Hospital for the Treatment of Mycotic Diseases, Banja Luka, Yugoslavia Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 69, Issue 4, 1 April 1957, Pages 145–147, https://doi.org/10.1111/j.1365-2133.1957.tb13245.x Published: 01 April 1957
Abstract 1317: Progression Of Carotid Intima-media Thickness Is Associated With Platelet-leucocyte Activation In Patients With Diabetes mellitus Type 2.
Authors: Suzanne Fateh-Moghadam, Patrik Htun, Ursula Plockinger, Thomas Reuter, Wolfgang Bocksch, Rainer Dietz, Meinrad Gawaz
Journal: Circulation (2007)
Pharmacokinetics of Nelarabine and 9-Beta-<scp>d</scp>-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic Malignancies
Authors: David F. Kisor, William Plunkett, Joanne Kurtzberg, Beverly Mitchell, Jeffrey P. Hodge, Timothy Ernst, Michael J. Keating, Varsha Gandhi
Journal: Journal of Clinical Oncology (2000)

PURPOSE: To characterize the pharmacokinetics of nelarabine (506U78), the water-soluble prodrug of 9-beta-d-arabinofuranosyl guanine (ara-G), and ara-G in pediatric and adult patients with refractory hematologic malignancies. Ara-G is phosphorylated within leukemic cells to form ara-G triphosphate (ara-GTP), which acts to terminate DNA chain elongation, resulting in cell death. PATIENTS AND METHODS: The pharmacokinetics of nelarabine and/or ara-G were evaluated in 71 patients (25 pediatric and 46 adult patients) on the first day of therapy. Blood was collected at specified times for the determination of plasma nelarabine and ara-G concentrations. RESULTS: There were no statistically significant differences in the pharmacokinetics of nelarabine between any of the groups of patients. The harmonic mean half-life (t1/2) of nelarabine in pediatric and adult patients was 14.1 minutes and 16.5 minutes, respectively. The maximum concentrations (C max ) of ara-G occurred at or near the end of the nelarabine infusion. The C max of ara-G ranged from 11.6 μmol/L to 308.7 μmol/L at nelarabine doses of 5 to 75 mg/kg and was linearly related to the nelarabine dose. No statistically significant differences were noted for the pharmacokinetic parameter estimates of ara-G between adult male and female patients. In children versus adults, the dose-normalized C max , time of the C max , and the steady-state volume of distribution of ara-G were similar. However, the clearance of ara-G was higher in pediatric patients (0.312 L·h −1 ·kg −1 ) as compared with adult patients (0.213 L·h −1 ·kg −1 ) (P &lt; .001). The t1/2 of ara-G was shorter in pediatric patients as compared with adult patients (2.1 hours v 3.0 hours; P &lt; .01). CONCLUSION: Nelarabine is an effective prodrug of ara-G, allowing systemic concentrations of ara-G that result in clinical activity.
Health-related quality of life in subjects with respiratory diseases: Preliminary results from the GEIRD study
Authors: Veronica Cappa, Maria Elisabetta Zanolin, Giancarlo Pesce, Mario Olivieri, Marcello Ferrari, Silvia Sembeni, Roberto de Marco
Journal: European Respiratory Journal (2011)

Health-related quality of life (HRQL) is an important outcome measure in patients with respiratory diseases. This study aims at investigating HRQL in different respiratory disorders.  Controls and cases of COPD, current asthma, past asthma, non-allergic rhinitis, allergic rhinitis and “Other Respiratory Conditions” (ORC) (n= 321, 29, 224, 125, 79, 130, and 148 respectively) were recruited in the frame of the nested multi-case control Genes Environment Interactions in Respiratory Diseases (GEIRD) study. HRQL was measured using SF-36 questionnaire. Medians of physical and mental component scores (PCS and MCS respectively) were estimated by quantile regression models adjusting for potential confounders.  PCS and MCS median scores of controls were respectively 54.8 (95%CI 54.2-55.3) and 52.0 (95%CI 50.9-53.2) and were significantly different from all phenotypes except rhinitis and past asthma cases; in particular, PCS median score ranged from 49.4 (95%CI 47.6-51.2) for COPD cases to 53.0 (95%CI 52.2-53.9) for current asthma cases and MCS score from 47.9 (95%CI 44.3-51.5) for COPD cases to 49.9 (95%CI 48.6-51.2) for current asthma cases (Tab1).  To our knowledge, this is the first study to perform a direct and simultaneous comparison of quality of life in several respiratory disorders. Subjects who suffer from COPD, current asthma and ORC had poorer HRQL than controls.
Microbiota-Dependent Activation of an Autoreactive T Cell Receptor Provokes Autoimmunity in an Immunologically Privileged Site
Authors: Reiko Horai, Carlos R. Zárate-Bladés, Patricia Dillenburg-Pilla, Jun Chen, Jennifer L. Kielczewski, Phyllis B. Silver, Yingyos Jittayasothorn, Chi-Chao Chan, Hidehiro Yamane, Kenya Honda, Rachel R. Caspi
Journal: Immunity (2015)
Pubertal growth in young adult survivors of childhood leukemia.
Authors: E Didcock, H A Davies, M Didi, A L Ogilvy Stuart, J K Wales, S M Shalet
Journal: Journal of Clinical Oncology (1995)

PURPOSE To determine the effect of cranial irradiation (18 Gy and 24 Gy) on pubertal growth in young adult survivors of childhood acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS Final height (FH) and pubertal growth were retrospectively examined in 142 young adult survivors of childhood ALL. All were in first remission and had received either 18 or 24 Gy of cranial irradiation. Eighty-four children (48 girls) were treated with 24 Gy and 58 (35 girls) with 18 Gy. None had received either testicular or spinal irradiation. Timing and duration of puberty were studied in 110 patients. RESULTS Significant reduction in height standard deviation score (SDS) from diagnosis to FH was seen in both sexes and in both dose groups. In girls, in both dose groups, mean age at peak height velocity (PHV) and mean age at menarche occurred significantly earlier than in the normal population. In boys, there was a normal timing of PHV. The amplitude of PHV was significantly reduced in both sexes and in both dose groups. Parameters of pubertal duration (PHV to menarche, PHV to FH, and menarche to FH) were not significantly different from normal population values. CONCLUSION In conclusion, puberty occurred early in girls, but not in boys. Amplitude of PHV was reduced in both sexes, with no reduction in the duration of puberty. It is likely that disturbances of both timing and quality of growth during puberty contribute to the loss of standing height and body disproportion seen in these children.
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Authors: Lieping Chen, Xue Han
Journal: Journal of Clinical Investigation (2015)

Major progress has been made toward our understanding of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway (referred to as the PD pathway). mAbs are already being used to block the PD pathway to treat human cancers (anti-PD therapy), especially advanced solid tumors. This therapy is based on principles that were discovered through basic research more than a decade ago, but the great potential of this pathway to treat a broad spectrum of advanced human cancers is just now becoming apparent. In this Review, we will briefly review the history and development of anti-PD therapy, from the original benchwork to the most up-to-date clinical results. We will then focus the discussion on three basic principles that define this unique therapeutic approach and highlight how anti-PD therapy is distinct from other immunotherapeutic approaches, namely tumor site immune modulation, targeting tumor-induced immune defects, and repairing ongoing (rather than generating de novo) tumor immunity. We believe that these fundamental principles set the standard for future immunotherapies and will guide our efforts to develop more efficacious and less toxic immune therapeutics to treat human cancers.
Agmatine Inhibits Cell Proliferation and Improves Renal Function in Anti—Thy-1 Glomerulonephritis
Authors: SHUNJI ISHIZUKA, ROBYN CUNARD, SIRIA POUCELL-HATTON, LUCINDA WEAD, MARK LORTIE, SCOTT C. THOMSON, FRANCIS B. GABBAI, JOSEPH SATRIANO, ROLAND C. BLANTZ
Journal: Journal of the American Society of Nephrology (2000)

Abstract. Changes in the expression of alternate arginine metabolic pathways have been implicated in the pathogenesis of experimental glomerulonephritis. Agmatine, decarboxylated arginine, has been shown in vitro to suppress both inducible nitric oxide synthase and the rate-limiting enzyme of polyamine biosynthesis, ornithine decarboxylase (ODC). This study was undertaken to determine whether agmatine administration could reduce tissue injury by decreasing nitric oxide, and reduce cell proliferation, by diminishing ODC activity, in experimental mesangial proliferative glomerulonephritis (Thy-1 nephritis). Agmatine treatment (50 mg/kg per d intraperitoneally) in Thy-1 nephritis rats prevented a reduction in GFR at day 1. Agmatine treatment decreased nitric oxide production in Thy-1 nephritis rats by 23% and 41% at days 1 and 4, respectively. Agmatine treatment also reduced ODC activity and glomerular 3H-thymidine incorporation on days 1, 4, and 7. Histologic evaluation revealed a decline in mesangial cell proliferation and extracellular matrix accumulation associated with agmatine treatment administered before or 24 h after Thy-1 antibody, and this was confirmed by a reduction in the number of cells expressing proliferating cell nuclear antigen on days 4 and 7. These studies provide the first in vivo evidence that agmatine administration can reduce cellular proliferation in Thy-1 nephritis and attenuate the initial reduction in renal function associated with this model.
Possible modifier effects of keratin 17 gene mutation on keratitis-ichthyosis-deafness syndrome
Authors: K. Natsuga, S. Shinkuma, M. Kanda, Y. Suzuki, N. Chosa, Y. Narita, M. Setoyama, W. Nishie, M. Akiyama, H. Shimizu
Journal: British Journal of Dermatology (2011)

Journal Article Possible modifier effects of keratin 17 gene mutation on keratitis–ichthyosis–deafness syndrome Get access K. Natsuga, K. Natsuga Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15 West 7, Sapporo 060‐8638, Japan Search for other works by this author on: Oxford Academic Google Scholar S. Shinkuma, S. Shinkuma Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15 West 7, Sapporo 060‐8638, Japan Search for other works by this author on: Oxford Academic Google Scholar M. Kanda, M. Kanda Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15 West 7, Sapporo 060‐8638, Japan Search for other works by this author on: Oxford Academic Google Scholar Y. Suzuki, Y. Suzuki Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15 West 7, Sapporo 060‐8638, Japan Search for other works by this author on: Oxford Academic Google Scholar N. Chosa, N. Chosa Department of Dermatology, University of Miyazaki Faculty of Medicine, Miyazaki, Japan Search for other works by this author on: Oxford Academic Google Scholar Y. Narita, Y. Narita Department of Dermatology, University of Miyazaki Faculty of Medicine, Miyazaki, Japan Search for other works by this author on: Oxford Academic Google Scholar M. Setoyama, M. Setoyama Department of Dermatology, University of Miyazaki Faculty of Medicine, Miyazaki, Japan Search for other works by this author on: Oxford Academic Google Scholar W. Nishie, W. Nishie Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15 West 7, Sapporo 060‐8638, Japan Search for other works by this author on: Oxford Academic Google Scholar M. Akiyama, M. Akiyama Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15 West 7, Sapporo 060‐8638, JapanDepartment of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan E‐mail: natsuga@med.hokudai.ac.jp Search for other works by this author on: Oxford Academic Google Scholar H. Shimizu H. Shimizu Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15 West 7, Sapporo 060‐8638, Japan Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 166, Issue 4, 1 April 2012, Pages 903–905, https://doi.org/10.1111/j.1365-2133.2011.10696.x Published: 01 April 2012
Sex, Lies, and HIV
Authors: S D Cochran, V M Mays
Journal: New England Journal of Medicine (1990)

Reducing the risk of human immunodeficiency virus (HIV) transmission among sexually active teenagers and young adults is a major public health concern. 1 Young people are advised to select potential sexual partners from groups at lower risk for HIV, 2 in part by asking about partners' risk histories. 3Unfortunately, this advice overlooks the possibility that people may lie about their risk history.
Human Immune Response to Active Immunization With Rauscher Leukemia Virus. II. Humoral Immunity2
Authors: E. M. Hersh, M. G. Hanna, J. U. Gutterman, G. Mavligit, M. Yurconic, C. R. Gschwind
Journal: JNCI Journal of the National Cancer Institute (1974)

Of 20 patients immunized with 100 μg formalin-killed Rauscher leukemia virus (RLV) every 2 weeks for 8 weeks, 10 developed a significant antibody titer as measured by a radioimmunoprecipitation assay. Among the responders, the mean titer, taken as the reciprocal of the highest serial twofold dilution yielding 50% virus precipitation, was ≈ 1:354. Antibody first appeared 2 weeks after immunization and reached a peak at 8 weeks. Antibody responses were most vigorous in patients with melanoma and in those receiving BCG plus chemotherapy; responses were least vigorous in patients with other solid tumors or acute leukemia, and in those receiving chemotherapy without immunotherapy. Correlation was excellent between the antibody response and the development of delayed hypersensitivity to the virus (P=0.005) and between the antibody response and in vitro lymphocyte blastogenic response to an antigen solubilized from RLV-infected cells (P=0.025). Extensive absorption studies indicated that sera from both immunized and nonimmunized subjects contained antimouse antibody. After in vivo absorption in mice, patients' postimmunization sera retained antiviral activity.
Are 30 minutes of rest between two incremental shuttle walking tests enough for cardiovascular variables and symptoms to return to baseline values
Authors: Laís Regina Ribeiro, Rafael Mesquita, Myriam Fernanda Merli, Cristiane Gonçalves, Daniela Hayashi, Josiane Felcar, Vanessa Suziane Probst
Journal: European Respiratory Journal (2012)

Background:  The Incremental Shuttle Walking Test (ISWT) is commonly performed twice for purposes of reproducibility, with in general, 30 minutes of rest between the tests. However, it is unknown if the 30 minutes9 rest is sufficient for stabilization of cardiovascular and symptomatological variables.  Aim:  To investigate if 30 minutes of rest between two ISWTs are enough for cardiovascular and symptomatological variables to return to baseline values in healthy subjects of different ages.  Methods:  457 healthy subjects (154 men, 63[45-70] years, 27[24-30] kg/m 2 ) were assessed and separated into quartiles according to their age: Q1 (18 to 45 years, n=117), Q2 (46 to 63 years, n=116), Q3 (64 to 70 years, n=121) and Q4 (71 to 83 years, n=103). Two ISWTs were performed with at least 30 minutes of rest in between, and heart rate (HR), blood pressure (BP) and symptoms of dyspnea and fatigue were assessed before and after the tests.  Results:  The HR before the ISWT was higher in the second test compared to the first one in the whole group and in all subgroups (p Conclusions:  30 minutes of rest between two ISWTs are not enough for the cardiovascular system to return to baseline values in healthy subjects, regardless of age. For perceived symptoms of dyspnea, this amount of rest seems to be enough.
Allergic reactions to rifampicin in tuberculosis treatment
Authors: Fatma Chermiti Ben Abdallah, Ines Zayani, Amel Chtourou, Sofia Taktak, Ridha Mahouachi, Ali Ben Kheder
Journal: European Respiratory Journal (2011)

Introduction:  Immuno-allergic reactions to antituberculous treatment occur in 4 to 5% of cases and cause serious problem in the management of tuberculosis especially when due to major drug such as rifampicin.   Aim of the study:  To describe different allergic reactions to rifampicin, the means of their confirmation and their management.   Methods:  Retrospective study including all patients treated for tuberculosis (TB) and who developed allergic reactions to rifampicin between January 2000 and December 2009.   Results:  Twelve (12) patients were included with mean age of 42 years. Mean delay of symptoms was 30 days after antituberculous treatment onset. Cutaneous reactions were noted in 11 patients, fever in 5 patients and anaphylactic reactions in 2 patients. Two patients had thrombocytopenia with hemorrhagic syndrome and 4 had hepatic cytolysis. Rifampicin responsibility was admitted after interruption of all the treatment and reintroduction one by one in 10 patients. In 2 cases the occurrence of thrombocytopenia after interrupted use of rifampicin and normalization of platelet level when rifampicin was stopped, allowed diagnosis. In 6 cases allergic reactions to rifampicin was associated to other antituberculous drug allergy. Rapid oral desensitization to rifampicin was successfully conducted in 4 patients. In 8 patients, rifampicin was definitively stopped, substituted by other antituberculous drug in two patients.   Conclusion:  Severe allergic reactions to rifampicin are rare but can cause serious problem in tuberculosis management. In these cases rapid oral desensitization represent an interesting alternative.
Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer.
Authors: A L Abner, A Recht, T Eberlein, S Come, L Shulman, D Hayes, J L Connolly, S J Schnitt, B Silver, J R Harris
Journal: Journal of Clinical Oncology (1993)

The prognosis and factors that influence prognosis following salvage mastectomy in patients with recurrence in the treated breast after conservative surgery (CS) and radiation therapy (RT) were investigated.A total of 1,593 patients with stage I or II invasive breast cancer were treated following gross total excision of the tumor at the Joint Center for Radiation Therapy (JCRT) between 1968 and 1985. One hundred sixty-six of the 1,593 (10%) had subsequent recurrence in the breast. Of these, 123 had salvage mastectomy and constitute the study population. The recurrent tumor was predominantly invasive in 99 patients, noninvasive in 14, and focally invasive in 10. Following mastectomy, chemotherapy or hormonal therapy was administered to 29 patients. The median follow-up time was 39 months after salvage mastectomy.The 5-year actuarial rate of further local or distant relapse for the entire group was 41%. None of the 24 patients with focally invasive or noninvasive tumors had a subsequent relapse. In comparison, the 5-year actuarial rate of further relapse in the 99 patients with a predominantly invasive recurrence was 52% (P = .001). The method of detection of the recurrence, the age of the patient at initial diagnosis, the disease-free interval, and the location of the recurrence in the breast were not found to have a statistically significant association with the risk of further relapse.We conclude that the histology of the recurrent tumor is an important prognostic factor for the risk of further relapse. Patients with purely noninvasive or focally invasive tumors have an excellent prognosis following salvage mastectomy. In contrast, patients with predominantly invasive tumors are at substantial risk for further relapse.
Histopathology of idiopathic pulmonary arterial hypertension in patients with low or normal diffusion capacity
Authors: Esther Nossent, Pia Trip, Harm jan Bogaard, Anco Boonstra, Anton Vonk-Noordegraaf, Katrien Grunberg
Journal: European Respiratory Journal (2012)

Introduction: In patients with Idiopathic Pulmonary Arterial Hypertension (IPAH) a wide range of diffusion capacity for carbon monoxide (DLCO) values can be observed. Low DLCO in IPAH is associated with worse prognosis when compared to normal DLCO 1 .  Hypothesis: histopathological pattern(s) of pulmonary vasculopathy in IPAH differ between patients with low and normal DLCO.  Methods: We retrospectively analyzed the histopathological (combinations of) patterns of vasculopathy in IPAH patients with low and normal DLCO. Low DLCO was defined as lowest tertile of the bimodal distribution of DLCO-value in a series of 170 IPAH patients 1  (  45% pred.). DLCO in the upper 2 tertiles (≥ 45 % pred.) was defined as normal DLCO.  Results: Out of 170 IPAH patients, complete data sets were obtained in 20 patients: low DLCO N=10; normal DLCO N=10. Results are shown in table 1 (study is ongoing).  Conclusion: A PVOD/PCH-like pattern is more common in IPAH with low DLCO, while plexogenic arteriopathy prevails in IPAH with normal DLCO.  1. Trip  et al,  abstract this meeting.
CLASSIFICATION AND DIFFERENTIATION OF CUTANEOUS LYMPHOMAS*.
Authors: Gunter Burg, Otto Braun-Falco
Journal: British Journal of Dermatology (1975)

Journal Article CLASSIFICATION AND DIFFERENTIATION OF CUTANEOUS LYMPHOMAS: Enzyme‐cytochemical and immunocytological studies Get access Günter Burg, Günter Burg Dermatologische Klinik und Poliklinik der Ludwig‐Maximilians‐Universität, München, D‐8000 München 2, Frauenlobstrasse 9, West‐Germany Search for other works by this author on: Oxford Academic Google Scholar Otto Braun‐Falco Otto Braun‐Falco Dermatologische Klinik und Poliklinik der Ludwig‐Maximilians‐Universität, München, D‐8000 München 2, Frauenlobstrasse 9, West‐Germany Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 93, Issue 5, 1 November 1975, Pages 597–599, https://doi.org/10.1111/j.1365-2133.1975.tb02256.x Published: 01 November 1975
Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy
Authors: Jennifer A. Lo, David E. Fisher, Keith T. Flaherty
Journal: JAMA Oncology (2015)

This commentary argues that while cutaneous adverse effects are associated with better outcomes among patients undergoing treatment with pembrolizumab, further analysis is required to determine whether nonvitiligo cutaneous adverse effects contribute to the observed outcome.